Canada markets closed

Can-Fite BioPharma Ltd. (CANF)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.8400+0.0070 (+0.84%)
At close: 03:59PM EST

Can-Fite BioPharma Ltd.

10 Bareket Street
Kiryat Matalon PO Box 7537
Petah Tikva 4951778
Israel
972 3 924 1114
https://www.canfite.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Dr. Pnina Fishman Ph.D.Scientific Founder, CEO & Director644kN/A1948
Mr. Motti FarbsteinChief Operating & Financial Officer416kN/A1964
Dr. Sari Fishman Ph.D.VP of Bus. Devel.317kN/A1972
Dr. Ilan Cohn Ph.D.Co-Founder & ChairmanN/AN/A1954
Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D.Sr. Clinical AdvisorN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Corporate Governance

Can-Fite BioPharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.